Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA.
Earl H, et al. Among authors: hulme c.
Health Technol Assess. 2020 Aug;24(40):1-190. doi: 10.3310/hta24400.
Health Technol Assess. 2020.
PMID: 32880572
Free PMC article.
Clinical Trial.